Fidaxomicin is the major analog of a family of macrocyclic lactones, isolated independently by three different groups from cultures belonging to three different genera (Actinoplanes, Dactylosporangium and Micromonospora) known as lipiarmycin A3, tiacumicin B and clostomicin B1, respectively. Fidaxomicin is a narrow-spectrum antibiotic with excellent activity against Gram-positive bacteria, notably Clostridium difficile. Fidaxomicin acts in the gastrointestinal tract without undue disruption to gut microbial flora.
Fidaxomicin is soluble in ethanol, methanol, DMF or DMSO. Limited water solubility.
|Spectrum||Fidaxomicin is a narrow-spectrum antibiotic with excellent activity against Gram-positive bacteria, notably Clostridium difficile.|
|Microbiology Applications||Clostridium difficile (CDI) is the major cause of nosocomial infection, and new antimicrobials like Fidaxomicin that do not alter normal gut flora are being explored (Mullane and Gorbach, 2014).|
S (2011) Fidaxomicin: First-in-class macrocyclic antibiotic. Expert Rev. Anti-infective Ther. 9 (70):767-777 PMID 21810048
Omura S et al (1986) Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I. Production, isolation, and physico-chemical and biological properties. J. Antibiot (Tokyo) 39(10):1407-1412
Parenti F et al (1975) Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. J. Antibiot. 28:247